var data={"title":"Deferoxamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Deferoxamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5984?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=deferoxamine-drug-information\" class=\"drug drug_general\">see &quot;Deferoxamine: Drug information&quot;</a> and <a href=\"topic.htm?path=deferoxamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Deferoxamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157271\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Desferal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157272\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Deferoxamine Mesylate for Injection;</li>\n      <li>Desferal;</li>\n      <li>PMS-Deferoxamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057708\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Aluminum Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Iron Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Chelating Agent, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15898662\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>Acute iron intoxication:</b> Very limited data available: IV infusion: 5 mg/kg/hour; dosing based on a case report of an oral ferrous sulfate overdose in a former premature neonate (GA: 27 weeks and age at time of treatment PCA: 34 weeks) (Valentine 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057699\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=deferoxamine-drug-information\" class=\"drug drug_general\">see &quot;Deferoxamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute iron intoxication:</b> Limited data available: Children and Adolescents: <b>Note:</b> The IV route is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone 2011). When severe symptoms are not present, then IM may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial: 15 mg/kg/hour and reduce rate as clinically indicated; maximum daily dose: 80 mg/kg/<b>day</b> and not to exceed 6 <b>g</b>/<b>day</b> (Desferal prescribing information [Canada; UK] 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 20 mg/kg (maximum dose: 1,000 mg) administered no faster than 15 mg/kg/hour followed by 10 mg/kg (maximum dose: 500 mg) over 4-hour intervals for 2 doses; subsequent doses of 10 mg/kg (maximum dose: 500 mg) over 4 to 12 hours may be repeated depending upon the clinical response; maximum dose: 6 <b>g</b>/<b>day</b>; this dosing may also be used IM if symptoms not severe</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 90 mg/kg/dose for one dose, then 45 mg/kg/dose every 4 to 12 hours as needed; maximum single dose: Children: 1,000 mg; Adults: 2,000 mg; maximum daily dose: 6 <b>g</b>/<b>day</b> (Desferal prescribing information [Canada; UK] 2010); others have used 50 mg/kg/dose every 6 hours with maximum daily dose: 6 <b>g/day</b> (Chang 2011); may also use intermittent IV dosing (see above)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic iron overload:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General dosing:</i> Manufacturer's labeling: Children &ge;3 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Growing Adolescents: 20 to 40 mg/kg/day over 8 to 12 hours, 5 to 7 days per week, usual maximum daily dose: 40 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents once growth has ceased: 40 to 50 mg/kg/day over 8 to 12 hours, 5 to 7 days per week, usual maximum daily dose: 60 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ infusion via a portable, controlled infusion device: 20 to 40 mg/kg/day over 8 to 12 hours 3 to 7 days per week; maximum daily dose: 2,000 mg/<b>day</b>. Doses &gt;60 mg/kg/day have not been shown to provide additional benefit (Vlachos 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sickle cell disease, chronic iron overload:</i> Children and Adolescents: SubQ infusion: 25 mg/kg/day over 8 hours; dose and duration may be increased as needed (NHLBI 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Thalassemia, chronic iron overload:</i>\n      <b> Note:</b> A lower dose may be required if the ferritin levels are low. In general, the therapeutic index should be kept &lt;0.025 at all times. Therapeutic index = mean daily deferoxamine dose (mg/kg)/ferritin (mcg/L) (Cappellini 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Growing Adolescents: SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents once growth has ceased:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ infusion (preferred): 40 to 60 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ bolus: 45 mg/kg/dose, 5 times per week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aluminum-induced bone disease in chronic renal failure:</b> Limited data available: Children and Adolescents: <b>Note:</b> Intended for predialysis serum aluminum concentration of 60 to 200 mcg/L; do not start chelation therapy if serum aluminum concentration &gt;200 mcg/L; intensive dialysis (6 days per week with a high flux dialysis membrane) should be used until serum aluminum concentration decreases below 200 mcg/L (National Kidney Foundation 2003):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Test (diagnostic) dose: IV: 5 mg/kg as a single dose infused over the last hour of dialysis; measure serum aluminum concentration 2 days later; depending upon the change in serum aluminum concentration, treatment with deferoxamine may be indicated (see Treatment below)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Monitor serum aluminum levels closely. See National Kidney Foundation guidelines for additional details on treatment algorithms.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aluminum serum concentration rise to &ge;300 mcg/L or adverse effects with test dose: IV: 5 mg/kg once a week 5 hours before dialysis for 4 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aluminum serum concentration rise to &lt;300 mcg/L: IV: 5 mg/kg once a week during the last hour of dialysis for 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute iron intoxication: Note:</b> The IV route is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (Perrone 2011). When severe symptoms are not present, then IM route may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 1,000 mg stat, then 500 mg every 4 hours for 2 doses, additional doses of 500 mg every 4 to 12 hours may be needed depending upon the clinical response; maximum daily dose: 6 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic iron overload: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 500 to 1,000 mg/dose; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 40 to 50 mg/kg/day over 8 to 12 hours for 5 to 7 days per week; maximum daily dose: 6 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ via portable, controlled infusion device: 1,000 to 2,000 mg/day or 20 to 40 mg/kg/day over 8 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Severe renal disease or anuria: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: The following adjustments have been recommended (Aronoff 2007): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute or CRRT: Administer 25% to 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute, hemodialysis, or peritoneal dialysis: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (not studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157252\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desferal: 500 mg (1 ea); 2 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157237\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057713\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Preferred route of administration for acute iron ingestion in patients not in shock per the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Administer as intermittent IV infusion or as continuous IV infusion; maximum rate: 15 mg/kg/hour; may consider reducing infusion rate to &lt;125 mg/hour after the first 1,000 mg have been infused. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: When administered for chronic iron overload, administration over 8 to 12 hours using a portable infusion pump is generally recommended; however, longer infusion times (24 hours) may also be used. Topical anesthetic or glucocorticoid creams may be used for induration or erythema (Brittenham 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157266\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store at  &le;25&#730;C (&le;77&deg;F). Following reconstitution, may be stored at room temperature for 24 hours, although the manufacturer recommends use begin within 3 hours of reconstitution. Do not refrigerate reconstituted solution. When stored at 30&#730;C in polypropylene infusion pump syringes, deferoxamine 250 mg/mL in sterile water for injection retained 95% of initial concentration for 14 days (Stiles 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057712\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct treatment of acute iron intoxication and treatment of chronic iron overload secondary to multiple transfusions (FDA approved in ages &ge;3 years and adults); has also been used in the diagnosis and treatment of aluminum accumulation in chronic renal failure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157321\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deferoxamine may be confused with cefuroxime, deferasirox, deferiprone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desferal may be confused with desflurane, Desyrel, Dexferrum</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Desferal [U.S., Canada, and multiple international markets] may be confused with Deseril brand name for methysergide [Australia, Belgium, Great Britain, Netherlands]; Disophrol brand name for dexbrompheniramine and pseudoephedrine [Czech Republic, Poland, Turkey]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157318\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing, hypotension, shock, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Brain disease (aluminum toxicity/dialysis-related), dizziness, headache, neuropathy (peripheral, sensory, motor, or mixed), paresthesia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Growth suppression (children), hyperparathyroidism (aggravated), hypocalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysuria, urine discoloration (reddish  color)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Dysplasia (metaphyseal; children &lt;3 years; dose related), leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatic insufficiency, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis (with or without shock), angioedema, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection (<i>Yersinia</i>, mucormycosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (burning, crust, edema, erythema, eschar, induration, infiltration, irritation, pain, pruritus, swelling, vesicles, wheal formation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, cataract, chromatopsia, corneal opacity, decreased peripheral vision, decreased visual acuity, nocturnal amblyopia, optic neuritis, retinal pigment changes, scotoma, vision loss, visual field defect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss, tinnitus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute renal failure, increased serum creatinine, renal tubular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Acute respiratory distress (dyspnea, cyanosis, and/or interstitial infiltrates), asthma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157258\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to deferoxamine or any component of the formulation; patients with severe renal disease or anuria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157241\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acute respiratory distress syndrome (ARDS): Deferoxamine has been associated with ARDS following excessively high-dose IV treatment of acute iron intoxication or thalassemia; has been reported in children and adults. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Auditory effects: Auditory disturbances (tinnitus and high frequency hearing loss) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for hearing loss. Audiology exams are recommended with long-term treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Growth retardation: High deferoxamine doses and concurrent low ferritin levels are also associated with growth retardation. Growth velocity may partially resume to pretreatment rates after deferoxamine dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Patients with iron overload are at increased susceptibility to infection with <i>Yersinia enterocolitica</i> and <i>Yersinia pseudotuberculosis;</i> treatment with deferoxamine may enhance this risk; if infection develops, discontinue therapy until resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion reactions: Flushing of the skin, hypotension, urticaria, and shock are associated with rapid IV infusion; administer by slow IV infusion, IM, or slow subcutaneous infusion only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mucormycosis: Rare and serious cases of mucormycosis (including fatalities) have been reported with use; withhold treatment with signs and symptoms of mucormycosis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular effects: Ocular disturbances (blurred vision; cataracts; corneal opacities; decreased visual acuity; impaired peripheral, color, and night vision; optic neuritis; retinal pigment abnormalities; retinopathy; scotoma; visual loss/defect) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for ocular disorders. Periodic ophthalmic exams are recommended with long-term treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal effects: Increases in serum creatinine, acute renal failure and renal tubular disorders have been reported; monitor for changes in renal function. Deferoxamine is readily dialyzable. When iron is chelated with deferoxamine, the chelate is water-soluble and is excreted renally.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urine discoloration: Patients should be informed that urine may have a pink, reddish, or orange discoloration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum toxicity: Treatment with deferoxamine in patients with aluminum toxicity may cause hypocalcemia and aggravate hyperparathyroidism. Deferoxamine may cause neurological symptoms (including seizure) in patients with aluminum-related encephalopathy receiving dialysis and may precipitate dialysis dementia onset.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemochromatosis: Deferoxamine is <b>not</b> indicated for the treatment of primary hemochromatosis (treatment of choice is phlebotomy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ascorbic acid: Combination treatment with ascorbic acid (&gt;500 mg/day in adults) and deferoxamine may impair cardiac function (rare), effects are reversible upon discontinuation of ascorbic acid. If combination treatment is warranted, initiate ascorbic acid only after one month of regular deferoxamine treatment, do not exceed ascorbic acid dose of 200 mg/day for adults (in divided doses), 100 mg/day for children &ge;10 years of age, or 50 mg/day in children &lt;10 years of age; monitor cardiac function. Do not administer deferoxamine in combination with ascorbic acid in patients with preexisting cardiac failure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855784\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Growth retardation in pediatric patients especially in patients &le;3 years has been associated with high doses (&gt;60 mg/kg) and concurrent low ferritin levels; a reduction in deferoxamine dosage may partially improve growth velocity; monitor growth in children receiving chronic therapy closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299129\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157246\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13208&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day.  Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump.  Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prochlorperazine: Deferoxamine may enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157248\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802788\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Adverse events have been observed in animal reproduction studies. Toxic amounts of iron or deferoxamine have not been noted to cross the placenta; however, the metabolic effects of a maternal overdose may adversely affect the fetus. In case of acute iron toxicity, treatment during pregnancy should not be withheld (Chang 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057707\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum ferritin, iron, total iron binding capacity; CBC with differential, renal function tests, liver function tests,  growth velocity (including weight and height) every 3 months, ophthalmologic exam, and audiometry (with chronic use); blood pressure (with IV infusions)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis patients: Serum aluminum (yearly; every 3 months in patients on aluminum-containing medications) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum-induced bone disease: Serum aluminum 2 days following test dose; test is considered positive if serum aluminum increases &ge;50 mcg/L </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057711\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron, serum: Normal: 50-160 mcg/dL; peak levels &gt;500 mcg/dL associated with toxicity. Consider treatment in symptomatic patients with levels &ge;350 mcg/dL; toxicity cannot be excluded with serum iron levels &lt;350 mcg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum, serum: &lt;20 mcg/L (National Kidney Foundation, 2003) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157240\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Complexes with trivalent ions (ferric ions), primarily in the vascular space, to form ferrioxamine, which is eliminated in the urine by the kidneys. One hundred milligrams of deferoxamine will bind about 8.5 mg of free circulating elemental iron (85 mg per 1,000 mg dose) but does not remove iron from transferrin or hemoglobin. Binding of cytoplasmic free iron reduces the free iron-induced disruption of mitochondrial cell membranes and enzyme systems. Ferrioxamine may create a pink- to red- or orange-colored urine as it is being excreted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157257\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributed throughout body fluids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Plasma enzymes; binds with iron to form ferrioxamine (iron complex)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 14 hours; plasma: 20 to 30 minutes (Brittenham 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as unchanged drug and ferrioxamine); feces (via bile)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157260\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Deferoxamine Mesylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $49.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $15.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Desferal Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $40.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157261\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Desferal (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CU, CY, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, OM, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Desferin (ES);</li>\n      <li>Talifer (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 116.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brittenham GM, &ldquo;Iron-Chelating Therapy for Transfusional Iron Overload,&rdquo; <i>N Engl J Med</i>, 2011, 364(2):146-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/21226580/pubmed\" target=\"_blank\" id=\"21226580\">21226580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cappellini MD, Cohen A, Eleftheriou A, et al, &quot;Guidelines for the Clinical Management of Thallassemia,&quot; 2nd ed, Nicosia, Cyprus: Thalassaemia International Federation, November 2008. Available at http://www.thalassaemia.org.cy/pdf/Guidelines_2nd_revised_edition_EN.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chang TPY and Rangan C, &ldquo;Iron Poisoning-A Literature-Based Review of Epidemiology, Diagnosis, and Management,&rdquo; <i>Pediatr Emerg Care</i>, 2011, 27(10):978-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/21975503/pubmed\" target=\"_blank\" id=\"21975503\">21975503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desferal (deferoxamine) [prescribing information]. Dorval, QC: Novartis Pharmaceuticals Canada Inc; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desferal (deferoxamine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Division of Blood Diseases and Resources, NHLBI, &quot;The Management of Sickle Cell Disease,&quot; Bethesda, MD: National Heart, Lung, and Blood Institute, 2002. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirking MH, &ldquo;Treatment of Chronic Iron Overload,&rdquo; <i>Clin Pharm</i>, 1991, 10(10):775-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/1742962/pubmed\" target=\"_blank\" id=\"1742962\">1742962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manoguerra AS, Erdman AR, Booze LL, et al, &quot;Iron Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management,&quot; <i>Clin Toxicol (Phila)</i>, 2005, 43(6):553-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/16255338/pubmed\" target=\"_blank\" id=\"16255338\">16255338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute (NHLBI). The Management of Sickle Cell Disease. Publication no. 02-2117. 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation, &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Failure,&quot; <i>Am J Kidney Dis</i>, 2003, 42(4 Suppl 3):1-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrone J, &ldquo;Iron,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiles ML, Allen LV, and Prince SJ, &ldquo;Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphone Hydrochloride, Lorazepam, and Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes,&rdquo; <i>Am J Health Syst Pharm</i>, 1996, 53(13):1583-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/8809281/pubmed\" target=\"_blank\" id=\"8809281\">8809281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valentine K, Mastropietro C, and Sarnaik AP, &ldquo;Infantile Iron Poisoning: Challenges in Diagnosis and Management,&rdquo; <i>Pediatr Crit Care Med</i>, 2009, 10(3):e31-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/19433938/pubmed\" target=\"_blank\" id=\"19433938\">19433938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vlachos A, Ball S, Dahl N, et al, &quot;Diagnosing and Treating Diamond Blackfan Anaemia: Results of an International Clinical Consensus Conference,&quot; <i>Br J Haematol</i>, 2008, 142(6):859-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/deferoxamine-pediatric-drug-information/abstract-text/18671700/pubmed\" target=\"_blank\" id=\"18671700\">18671700</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13208 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F157271\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157272\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057708\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F15898662\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057699\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157252\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F157237\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057713\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F157266\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057712\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F157321\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157318\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157258\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157241\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855784\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299129\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157246\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157248\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F802788\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057707\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1057711\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157240\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F157257\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F157260\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157261\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13208|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=deferoxamine-drug-information\" class=\"drug drug_general\">Deferoxamine: Drug information</a></li><li><a href=\"topic.htm?path=deferoxamine-patient-drug-information\" class=\"drug drug_patient\">Deferoxamine: Patient drug information</a></li></ul></div></div>","javascript":null}